Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Aly

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
European Urology|July 14, 2018
Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance ImagingHenrik Grönberg, Martin Eklund, Wolfgang Picker, et al.
The Lancet. Oncology|November 14, 2015
Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic studyHenrik Grönberg, Jan Adolfsson, Markus Aly, et al.
JAMA Network Open|November 7, 2019
Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy ResultsKerri Beckmann, Danielle Crawley, Tobias Nordström, et al.
Acta Oncologica (Stockholm, Sweden)|November 30, 2022
Cardiovascular, bone, and metabolic health in men with castrate-resistant prostate cancer treated with androgen deprivation: a matched cohort studyYashar Khoshkar, Hari T Vigneswaran, Sandra Eloranta, et al.
Journal of the National Cancer Institute|May 8, 2024
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonistsLars Björnebo, Shirin Razdan, Andrea Discacciati, et al.
Scandinavian Journal of Urology|April 9, 2020
Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in SwedenMarkus Aly, Amy Leval, Frida Schain, et al.
European Urology Open Science|April 24, 2023
Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate CancerAnna Lantz, Per Nordlund, Ugo Falagario, et al.
BJUI Compass|September 26, 2024
Long-term oncological outcomes after multimodal treatment for locally advanced prostate cancerFiorella L Roldan, Ugo Giovanni Falagario, Mats Olsson, et al.
European Urology Focus|July 30, 2017
The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer TestingMartin Eklund, Tobias Nordström, Markus Aly, et al.
Annals of Surgical Oncology|January 11, 2024
ASO Author Reflections: Arterial Ischemic Events Following Cancer Surgery: Where Do We Stand?Juhana Rautiola, Johan Björklund, Renata Zelic, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
European Urology|July 14, 2018
Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance ImagingHenrik Grönberg, Martin Eklund, Wolfgang Picker, et al.
The Lancet. Oncology|November 14, 2015
Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic studyHenrik Grönberg, Jan Adolfsson, Markus Aly, et al.
JAMA Network Open|November 7, 2019
Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy ResultsKerri Beckmann, Danielle Crawley, Tobias Nordström, et al.
Acta Oncologica (Stockholm, Sweden)|November 30, 2022
Cardiovascular, bone, and metabolic health in men with castrate-resistant prostate cancer treated with androgen deprivation: a matched cohort studyYashar Khoshkar, Hari T Vigneswaran, Sandra Eloranta, et al.
Journal of the National Cancer Institute|May 8, 2024
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonistsLars Björnebo, Shirin Razdan, Andrea Discacciati, et al.
Scandinavian Journal of Urology|April 9, 2020
Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in SwedenMarkus Aly, Amy Leval, Frida Schain, et al.
European Urology Open Science|April 24, 2023
Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate CancerAnna Lantz, Per Nordlund, Ugo Falagario, et al.
BJUI Compass|September 26, 2024
Long-term oncological outcomes after multimodal treatment for locally advanced prostate cancerFiorella L Roldan, Ugo Giovanni Falagario, Mats Olsson, et al.
European Urology Focus|July 30, 2017
The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer TestingMartin Eklund, Tobias Nordström, Markus Aly, et al.
Annals of Surgical Oncology|January 11, 2024
ASO Author Reflections: Arterial Ischemic Events Following Cancer Surgery: Where Do We Stand?Juhana Rautiola, Johan Björklund, Renata Zelic, et al.
Pageof 9